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ABST RACT
Within its twisted and tight walls, where a hostile and arid environment prevails,
the lumen of the digestive tract nests a true microuniverse called the microbiota.
The existing relationship between humans and these microorganisms is one in
which both benefit, creating a condition called Eubiosis.
The dynamic relationship existing between the microbiota and the human body
can be affected at various times, leading to an imbalance that may have
important implications on health and generating a condition called Disbiosis.
Recent studies have highlighted possible links between several diseases with
incompletely elucidated etiology and disturbances of the microbiota. In this
review we aim to analyze the existing relationship between the imbalances of the
gastrointestinal flora and the etiopathogeny inflammatory bowel diseases, a
group of diseases whose incidence has increased considerably in recent years.

Introduction
There are over 100 trillion microorganisms at the level
of the gastrointestinal tract (GI), which make up a
complex biosystem called the microbiota. The
composition of the microbiota is vast, containing entities
belonging to all domains of life: Eukarya Bacteria and
Archaea. Broadly, the main components that make up the
structure of this microuniverse belong to the bacteria
group and are represented by species from four major
phyla: Actinobacteria, Proteobacteria, Bacteroidetes, and
Firmicutes [1].
Between the human body and the microbiota is
established a dynamic and very complex relationship,
alteration of this biosystem sometimes causing adverse
consequences on the health status. The functions of the GI
flora depend on its composition/ biocharacteristics of the
species, having implications for the following processes:
modulation of the digestion process, regulation of
immunity, biosynthesis of vitamins, and harvesting
energy [2-6].
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Alteration of the structure - and thus of the functionof the microbiota bears the name of dysbiosis, a condition
linked to numerous pathological conditions such as type 2
diabetes, obesity, cancer, autoimmune disorders, and
allergies [7-13].
Inflammatory bowel diseases (IBD) represent a set of
gastrointestinal disorders with incompletely elucidated
etiology, which includes two distinct clinical and
pathological entities: Crohn’s disease (CD) and Ulcerative
Colitis (UC). IBD are characterized by inflammatory
impairment of the digestive tract, which present an
undulating evolution consisting of periods of remission
and relapse [14].

Discussions
IBD: Overview
IBD usually refers to two chronic pathological
conditions, represented by Crohn’s Disease and
Ulcerative Colitis. The main feature of IBD consists of
inflammation, which can be localized at any level of the
digestive tract.
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The clinical manifestations of these conditions are
dominated by gastrointestinal symptoms, ranging from
diarrhea to malabsorption, loss of nutrients as well as
digestive bleeding due to inflammation. These symptoms
are often accompanied by abdominal pain, severity
ranging from mild to severe (life-threatening) according
to the degree of the local/ intestinal inflammatory process.
The inflammation has generally a chronic clinical
evolution, marked by an alternation of remissions and
exacerbations [15].
The incidence and prevalence of these diseases are
globally increasing, the countries with the highest values
being those that are highly developed and industrialized,
such as North America and Northern Europe. Recent
investigations show that the incidence is stabilising or
slightly decreasing in developed countries, being
conversely rapidly increasing in countries that are in the
full process of industrialization, urbanization, and
westernization, such as in Asia, South America, and
Africa [16,17].

Microbiota and IBD
The etiology and pathophysiology of IBD are not
completely elucidated. IBD results from the complex
interaction of environmental and intestinal microbial
factors within a organism that has a genetic susceptibility,
which ultimately results in an abnormal immune response
partly disconnected from its own regulatory mechanisms
(Figure 1) [18].

Figure 1. Interaction of factors that are contributing to
IBD occurrence.
Recently, more emphasis has been placed on the
interaction between the intestinal flora and the host's
immune system, the presence of microorganisms at
intestinal level being a key element (if not mandatory) in the
genesis of this pathology [19]. The loss of tolerance for
intestinal bacteria (which triggers an immune response) may
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be one of the main explanations for pathogenesis of these
diseases [20]. This pathological process may be strongly
influenced by alteration in the composition, structure, and
function of the gut microbiota, a condition referred to as
dysbiosis. These assumptions are indirectly supported by the
positive results (good control of intestinal inflammation)
obtained after administration of gut flora regulators such as
probiotics, prebiotics, and antibiotics [21].
An important quantitative change found in the intestinal
flora of IBD patients is reduction of the bacterial load and
reduction of its diversity [22], the reduction of diversity
being described within the same individual, in the same
digestive segment, and between the areas affected by the
inflammatory process and the healthy ones [23].
The main qualitative changes in the composition of the
microbiota are represented in IBD patients by increases and
decreases of certain bacterial populations. An important
change in this balance is represented by an increase of the
harmful bacteria and a reduction in the population of
bacteria with a protective role on the digestive tract.
The reduction of protective bacterial species is usually
related to the following populations: gram-positive bacterias
(species from phyla Firmicutes), butyrate-producing
bacterias (Roseburia, Faecalibacterium prausnitzii), and
general protective species (from the genus Bifidobacterium)
[24, 25]. These changes are significant because all of these
species play an important role in maintaining the intestinal
homeostasis through a range of functions, such as:
production of short chain fatty acids, strengthening the
intestinal barrier, reduction of local and systemic
inflamation, and protection from pathogenic species of
bacteria. The protective role of these microorganisms in the
pathophysiology of IBD is supported by multiple research
studies. As an example, some studies have shown that
chemically induced intestinal inflammation induces clinical
manifestations that are more pronounced in mice with a
sterile gut, than in conventional mice having a digestive
tract populated with microorganisms [26].
The populations of harmfull bacterial species found to
be increased in IBD patients are represented by several
gram-negative bacteria (such as Proteobacteria,
Pasteurellaceae) and various opportunistic pathogens
(Escherichia coli, Fusobacteria, etc.), all these species
having as the main characteristic a proinflammatory effect
that is present both locally and systemically [27].
The manner in which the altered bacterial population
interacts with the internal environment (leading thus to
pathogenesis of IBD) is incompletely elucidated, but their
presence is quite well documented. In support of this, a
recent study proved that mice with a sterile gut do not
develop colitis, and this is possible only through insertion of
fecal matter containing bacteria [28].
Several mechanisms have been proposed to explain the
role of an altered intestinal microbiota in the development of
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the inflammatory process that is associated with
inflammatory bowel diseases. Such mechanisms are
represented by an increase in intestinal permeability leading
to bacterial translocation, synthesis of toxic products that
migrate into the internal environment due to increased
intestinal permeability (generating thus endotoxinemia),
disturbance of intestinal cell’s endoplasmic reticulum
homeostasis, and oxidative stress.
The increase in intestinal permeability could be a
consequence of reduction of the population of short-chain
fatty acid-producing bacteria. Endotoxinemia is caused by
production of toxic substances by bacteria (such as
Escherichia coli, Proteobacteria, Pasteurellaceae), migration
of toxic compounds being favored by the deficient intestinal
barrier. The functional alteration of the endoplasmic
reticulum can be induced by different bacterial species’
production of various toxic substances, which enter the
intestinal epithelial cells and are able to interfere with the
functionality of the endoplasmic reticulum (e.g. Escherichia
coli). Some species of bacterias (Escherichia coli,
Helicobacter pylori) can produce reactive oxygen, causing
oxidative stress in the digestive tract and thus contributing
to the maintenance of the inflammatory process [29].
In addition to bacterial abnormalities described for IBD,
it appears that intestinal viral and fungal populations also
exhibit a number of alterations, even if they represent an
extremely small part of the microbiota composition.
Regarding the changes found in the fungal population,
species belonging to the classes Basidiomycota, Candida
albicans, and Ascomycota have been found to be increased,
while the Saccharomyces cerevisiae population seems to be
decreased. The role of the fungal implication in
pathophysiology of IBD is incompletely elucidated,
literature data showing that molecules present on the fungal
wall surface (beta-glucans, chitin) are able to trigger the
innate immune response and thus to contribute to
maintenance of the inflammatory process [30].
The intestinal viral population of IBD patients is
characterized by a greater variability, with the expansion of
the bacteriophage-type population [31]. A recent study
revealed an increased bacteriophages class from the order
Caudovirales. At the level of the digestive tract, the
bacteriophages contribute not only to the maintenance of
bacterial homeostasis but also to the modulation of the
immune response. Even so, there is currently not enough
evidence to suggest that intestinal viral microbiota play an
essential role in the development and evolution of IBD [32].

Highlights
At the level of the gastrointestinal tract there are over
100 trillion microorganisms that make up the microbiota.
Alteration of the structure and the function of the
microbiota, known as dysbiosis, has been linked to

numerous pathological conditions such as type 2 diabetes,
obesity, cancer, autoimmune disorders, and allergies.
Inflammatory bowel diseases result from the complex
interaction of environmental and intestinal microbial
factors, within an organism that generally has a genetic
susceptibility.
The loss of tolerance for intestinal bacteria (which
often triggers an immune response) may be one of the
main explanations in the pathogenesis of this disease.
Some changes encountered in composition of the
microbiota are characterised by an increase/ abundance of
the harmful bacteria, and a reduction in the population of
bacteria with a protective role on the digestive tract.

Conclusions
IBD is a group of diseases whose incidence is still
increasing. With multiple complications and comorbidities,
and often debilitating clinical manifestations, IBD causes a
marked decrease in patients’ quality of life. The etiology
and pathogenesis of these diseases are incompletely
elucidated, the new researches emphasizing an important
role of the gut microbiota in the occurrence and progression
of such inflammatory diseases. Modulation of the
composition and structure of the commensal flora through
multiple therapeutic pathways (like probiotics, prebiotics,
antibiotics, and fecal transplantation) can determine
positive results and provide a better perspective for these
digestive conditions.
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